Aug 13, 2020
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis
Jun 15, 2020
Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper
Jun 03, 2020
Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline
May 22, 2020
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
Apr 23, 2020
REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
Apr 22, 2020
Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
Apr 21, 2020
Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study
Apr 09, 2020
Hoth Therapeutics Commences Next Phase of VNLG-152 Study
Apr 02, 2020
Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)
Mar 30, 2020
Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases
Mar 19, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
Mar 16, 2020
Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share
Feb 19, 2020
Hoth Therapeutics Receives Notice of Allowance from European Patent Office
Feb 12, 2020
Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
Feb 11, 2020
Hoth Therapeutics, Inc. to Present at 2020 Noble Capital Market's Sixteenth Annual Small-Cap Investor Conference
Jan 15, 2020
Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects
Dec 19, 2019
Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression
Dec 17, 2019
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board
Dec 12, 2019
The HOTH Launches it's Brand New Case Study Hub, featuring a collection of SEO and PPC success stories and insight
Dec 11, 2019
The HOTH Now Provides More Than 20 SEO Tools On Their Website That Anyone Can Use At No-Cost